Montana has enacted a new "right to try" law that aims to provide terminally ill patients with access to experimental drugs not yet approved by the FDA. One such patient, Kris DeVault, is seeking access to an experimental drug for his son Brody, who suffers from creatine transporter deficiency. While the drug shows promise in animal and early human trials, it is not yet approved and faces regulatory hurdles for broader access in the US, leaving DeVault concerned about his son's limited developmental window. AI
RANK_REASON The cluster discusses a new state law impacting access to experimental treatments, which is a significant policy development. [lever_c_demoted from significant: ic=1 ai=0.1]
Read on MIT Technology Review →
- Brody
- Ceres Brain Therapeutics
- creatine transporter deficiency
- Kris DeVault
- Montana
- Thomas Joudinaud
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
